AlphaYou
Overview
Smart money at a glance
Filings to Sep 28, 2026Net selling: insiders sold $8.2M and bought $0 on the open market in 90 days (SEC Form 4). Congress: net selling of $16K to $65K in 180 days.
- Company insidersSEC Form 4, last 90 days
- -$8.2M netNet selling
- CongressSTOCK Act, last 180 days
- -$16K to -$65K netNet selling
- Big fundsSEC 13F, quarter ended Jun 30, 2026
- 11 added, 2 cutMore adding
- Federal contractsUSAspending.gov, last 12 months
- 9 awardsAwards on record
Key stats
Fundamentals Sep 28- Open
- $265.49
- 52-wk high
- $269.39
- High
- $266.00
- 52-wk low
- $189.40
- Low
- $262.59
- Prev close
- $265.12
- Mkt cap
- $467.12B
- P/E
- 74.5x
- Volume
- 2.52M
- Fwd P/E
- 16.4x
- Beta
- 0.28
- Div yield
- 2.58%
- P/S
- 7.3x
- P/B
- 50.5x
- Profit margin
- +9.8%
- Op margin
- +40.0%
- ROE
- +62.3%
What do analysts expect?
Analyst target and ratings are on paid plans
See the 12-month consensus target and the buy/hold/sell rating split.
Unlock the full resultsQuestions about ABBV filings
Are insiders buying or selling AbbVie Inc (ABBV) stock?
Net selling: insiders sold $8.2M and bought $0 of ABBV stock on the open market in the 90 days to Sep 28, 2026, according to SEC Form 4 filings. The largest was Donoghoe, Nicholas (EVP, Chief Bus/Strat Officer), who sold $8.2M. The latest filing was on Aug 18, 2026.
Which members of Congress have traded ABBV recently?
Rep. Pete Sessions (R) sold $15K to $50K on Sep 14, 2026, disclosed 4 days later. Rep. Josh Gottheimer (D) sold $1K to $15K on May 5, 2026, disclosed 29 days later. In total, 2 members disclosed 2 ABBV trades with trade dates in the last 180 days, filed a median 17 days after trading.
How current is this ABBV smart-money data?
This summary uses filings available on Sep 28, 2026. Insiders must report trades to the SEC within 2 business days, members of Congress have up to 45 days to disclose a trade, and funds file 13F holdings up to 45 days after each quarter ends, so the latest moves may not be public yet.
Smart money
8 funds hold a position and insiders have been net selling.
What funds are doing
Buys/Adds (3)
- CI
Citadel
$691.0M
added
- DS
D.E. Shaw
$382.7M
added
- AQ
AQR
$313.8M
added
What insiders are doing
Sells (1)
- DN
Donoghoe Nicholas
$8.2M
sold
What Congress is doing
Sells (2)
How top traders are positioned
No tracked top-trader positions in ABBV right now.
Live Hyperliquid positioning - not every stock is covered
Earnings
Earnings landed in line with what analysts expected.
Earnings per share
$3.64 expected
Revenue
$16.76B expected
GAAP EPS was $2.03; adjusted EPS matches the analyst basis.
Reports Oct 30, 2026, in 32 days
Estimates as of Sep 27, 2026
EPS expected
$3.77 to $3.87
Revenue expected
18 analysts
Last 30 days
Analysts cutting estimates
What the company said
Financials
What it sold, what it cost, what was left.
| USD | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| What came in | ||||
| Revenue | $15.78B | $16.62B | $15.00B | $16.99B |
| Cost of what it sold | $5.30B | $4.55B | $4.22B | $4.29B |
| Gross profit | $10.47B | $12.07B | $10.78B | $12.70B |
| What it spent | ||||
| Research and development | $2.32B | $2.58B | $2.47B | $2.34B |
| Sales and admin | $3.57B | $3.90B | $3.58B | $3.63B |
| Other operating costs | $2.68B | -$217.0M | — | $291.0M |
| Total operating expenses | $8.57B | $6.26B | $6.05B | $6.27B |
| What was left | ||||
| Operating profit | $1.90B | $5.81B | $4.73B | $6.43B |
| Interest on debt | $739.0M | $714.0M | $717.0M | $746.0M |
| Profit before tax | $714.0M | $2.67B | $1.04B | $4.28B |
| Tax | $526.0M | $853.0M | $342.0M | $662.0M |
| Net profit | $186.0M | $1.82B | $699.0M | $3.61B |
| EBITDA | $3.52B | $5.37B | $3.69B | $8.66B |
Technicals
Price structure
This stock is in a strong uptrend.
Trend
Strong uptrend
100 / 100
RSI 14
20D volatility
52-week range
20D support
20D resistance
Returns
Price vs moving averages
Volume pace
News
What the news says
Coverage is bullish
Tone of tracked coverage
Investment Outlook Comparison: AbbVie vs. Pfizer
NeutralSep 25US FDA approves AbbVie's drug for Parkinson's disease
BullishSep 25AbbVie vs. Pfizer: Which Healthcare Stock Makes Your Portfolio Healthier in 2026?
Leans bullishSep 25AbbVie vs. Pfizer: Which Healthcare Stock Makes Your Portfolio Healthier in 2026?
NeutralSep 25Gene Silencing-Biotech ADARx Makes Some Noise With $535M Stock Market Debut
Leans bullishSep 25REGENXBIO reports three-year ALTITUDE DRSS data
NeutralSep 25ABBV vs. JNJ: One of These Dividend Aristocrats Will Crush the Other Over the Next Decade
NeutralSep 25ADARx Pharmaceuticals raised $446 million in a biotech IPO backed by AbbVie
BullishSep 25
Macro
31 macro signals shaping ABBV right now
Unlock sector rotation, regime shifts, and macro event windows tied to this stock.
Unlock the full results